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Selective hypermethylation is evident
in small intestine samples from infants
with necrotizing enterocolitis
Misty Good1*, Tianjiao Chu2,5, Patricia Shaw5, Lila S. Nolan3, Joseph Wrobleski5, Carlos Castro5, Qingqing Gong3,
Olivia DeWitt3, David N. Finegold4 and David Peters2,4,5,6*

Abstract
Objective: Necrotizing enterocolitis (NEC) is the most common and lethal gastrointestinal disease affecting preterm
infants. NEC develops suddenly and is characterized by gut barrier destruction, an inflammatory response, intestinal
necrosis and multi-system organ failure. There is currently no method for early NEC detection, and the pathogenesis
of NEC remains unclear.
Design: To further understand the molecular mechanisms that support NEC, we used solution phase hybridization
and next-generation DNA sequencing of bisulfite converted DNA to perform targeted genome-wide analysis of DNA
methylation at high read depth.
Results: We found that ileal samples from surgical NEC infants (n = 5) exist in a broadly hypermethylated state relative to their non-NEC counterparts (n = 9). These trends were not uniform, with hypermethylation being most consistently observed outside CpG islands and promoters. We further identified several biologically interesting gene promoters that displayed differential methylation in NEC and a number of biological pathways that appear dysregulated in
NEC. We also found that DNA methylation patterns identified in ileal NEC tissue were correlated with those found and
published previously in stool samples from NEC-affected infants.
Conclusion: We confirmed that surgical NEC is associated with broad DNA hypermethylation in the ileum, and this
may be detectable in stool samples of affected individuals. Thus, an epigenomic liquid biopsy of stool may have significant potential as a biomarker with respect to the diagnostic/predictive detection of NEC. Our findings, along with
recent similar observations in colon, suggest that epigenomic dysregulation is a significant feature of surgical NEC.
These findings motivate future studies which will involve the longitudinal screening of samples obtained prior to the
onset of NEC. Our long-term goal is the development of novel screening, diagnostic and phenotyping methods for
NEC.
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Introduction
Necrotizing enterocolitis (NEC) remains one of the overall leading causes of death in premature infants in the
neonatal intensive care unit (NICU) [1–3], and the precise etiology is not well understood. This devastating disease develops suddenly in 10% of premature infants, with
half of the affected neonates requiring surgical excision
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of the necrotic intestine, and the associated mortality
rate is as high as 50% [4]. Currently, there is no available
method to predict the onset of NEC in at-risk infants.
The treatment for NEC and the survival rate of infants
afflicted by NEC have not changed over the past 40 years,
with approximately $2–3 billion per year spent treating
the disease [5–7].
A challenge in the management of NEC involves the
absence of effective and predictive biomarkers, resulting
in an inability to identify neonates at high risk of NEC
development who may benefit from early preventative
strategies. The importance of predicting NEC before
the onset of disease is defined by three principles. First,
by delineating the factors predictive of NEC, we will
improve our understanding of the mechanisms and biologic pathways that lead to the exaggerated inflammatory
response in NEC. Second, the use of predictors for NEC
permits the identification of infants at the highest risk for
whom an intervention may be tested and for whom intervention is most critically needed. The third motivation
for the prediction of NEC is a corollary of the second;
by identifying infants at low risk of NEC, unnecessary,
costly, and sometimes hazardous interventions might be
avoided.
A primary aim of this study was to determine the
molecular phenotype of NEC through an epigenomic
analysis of the ileum, with a specific focus on DNA methylation. Our interest in DNA methylation is motivated
by its potential as a stool biomarker for early detection
of NEC. Importantly, our previous studies have identified a significant degree of global hypermethylation in
the NEC ileum via whole-genome bisulfite sequencing
of laser captured enterocytes [8]. In this study, we aimed
to expand these findings through targeted genome-wide
analysis by solution phase hybridization to generate high
read depth methylation sequencing data within wellcharacterized regions of the genome containing known
genes and regulatory elements.

non-inflammatory indications (such as re-anastomosis,
spontaneous intestinal perforation or anorectal malformation). In some instances, deidentified intestinal samples were obtained with a waiver of consent and approval
of University of Pittsburgh IRB (PRO14070508). For
these cases, the clinical information obtained was limited
to the location of the resected intestinal tissue sample
and the surgical indication. Resections of intestinal tissue
were snap-frozen and stored at -80 degrees Celsius until
further analysis. Non-NEC tissue samples in this study
are from patients after NEC had healed obtained during
the surgical re-anastomosis. The use of healed NEC tissue
obtained in this manner is standard in this field as infants
can then serve as their own control. Complete information about neonatal sex for all surgically resected samples
was unable to be obtained due to the deidentified nature
of the way in which tissue was collected; therefore, we
analyzed only autosomal genomic loci to minimize the
impact of sex differences on our findings.

Methods

Bisulfite sequencing of solution phase captured DNA
fragments was carried out as previously described [9].
DNA was sheared with Covaris to a size of ~ 175 bp.
Libraries were prepared using the KAPA HyperPrep Kit
(Roche). Libraries were bisulfite converted post-ligation
using the EZ DNA Methylation-Direct Kit (Zymo) and
amplified 13–15 cycles. Bisulfite-converted DNA libraries underwent targeted capture using the SeqCap Epi
CpGiant Enrichment Kit (Roche, Pleasanton, CA) and
amplified 10 cycles. Samples were sequenced on a HiSeq
2500 (Illumina) with 100 bp paired-end reads to a mean
targeted read depth of ~ 24 ×. DNA sequence reads were
quality trimmed and adaptor sequences were removed
using Trim-Galore (https://www.bioinformatics.babra

Study population and selection criteria

The intestinal samples in this study were collected
in accordance with the University of Pittsburgh anatomical tissue procurement guidelines. Collection was
approved by the Institutional Review Board (IRB) of the
University of Pittsburgh (Protocols PRO09110437 or
PRO14070508). Preterm infants were recruited under
Protocol PRO09110437 at either Children’s Hospital of
Pittsburgh (CHP) of University of Pittsburgh Medical
Center (UPMC) or Magee-Womens Hospital Neonatal
Intensive Care Units (NICUs), and consent was obtained
from their parent or legal guardian. Resected intestinal tissue samples were obtained due to NEC or other

DNA recovery from tissue sections

DNA recovery from ileal tissue sections was performed
as previously described [9]. Snap-frozen specimens
were mounted on appropriate embedding molds (Large,
Thermo Scientific #2219; or Small, Sakura Tissue—Tek
#4566) with clear OCT compound (Optimal Cutting
Temperature Embedding Medium) (Fisher HealthCare
#4585) and sectioned with a cryostat instrument (Leica
CM 1850 UV, 7 microns). These sections were mounted
on membrane slides (Leica PEN—Membrane Slide, 2.0
microns #11505158), stained with toluidine blue (Toluidine Blue 0.1% Aqueous, Newcomer Supply #14027),
and air-dried (Sampla Dry Keeper, Samplatec. Corp).
DNA was extracted from tissue sections using the Nucleospin Tissue XS Kit (Macherey–Nagel). Quantification of
extracted DNA was performed with the KAPA hgDNA
Quantification and QC Kit (Roche).
Bisulfite sequencing
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ham.ac.uk/projects/trim_galore/). The reads were aligned
to the human reference sequence (GRCh38/hg38) using
Bismark Bisulfite Read Mapper [10] in paired-end, bowtie2 mode. Any unmapped reads were aligned in single-end, bowtie2 mode. Read duplicates were removed
using Bismark. Methylation was called on paired-end
and single-end files and then merged to determine the
methylation status for each CpG site. DNA methylation
signatures were determined using the beta-binomial test
implemented in the R packages methylSig [11] and DSS
[12].

Results
Solution-phase hybridization was used to undertake
targeted genome-wide bisulfite sequencing of DNA
extracted from histological tissue sections of NEC ileum
(n = 5) and non-NEC ileum (n = 9). We sequenced a
total of 1,066,205,683 aligned read pairs across all samples. The targeted genomic regions collectively span
approximately 80 Mb of the human genome and includes
approximately 5.5 million CpG sites located within promoters, exons, introns, CpG islands (CGIs), CpG island
shores and enhancers.
Ileal NEC samples are broadly hypermethylated

In our targeted genomic analysis, we observed that ileal
NEC samples had extensive DNA hypermethylation
when compared to their non-NEC counterparts. This
trend was evident in the broadest sense but also detectable when considering different genomic elements. The
greatest effect was seen in regions without CGIs, whereas
those regions containing CGIs were either less likely to
be differentially methylated (CGIs in promoters) or displayed a bias toward hypomethylation in NEC (CGIs in
introns/exons and CGIs in intergenic regions). These differences in the distribution of DNA methylation between

NEC and non-NEC ileum samples were significant in all
genomic contexts tested (Table 1).
A density plot analysis revealed a bimodal distribution
of CpG methylation across all sites analyzed with peaks
representing hypo- and hypermethylated states (Fig. 1A).
These distributions varied when analyzing CpG sites in
specific genomic regions. Specifically, introns, exons and
intergenic regions that do not overlap with CGIs displayed a preponderance of hypermethylated sites (Fig. 1D
and H). In contrast, CGIs in promoter regions contained
very few hypermethylated CpG sites and, as expected,
were largely hypomethylated (Fig. 1C). NEC-specific
increases in CpG methylation were observed to varying
degrees in all contexts, especially when all CpG sites were
considered and in those genomic regions lacking CGIs
(Fig. 1A, B, D, G, H and Table 2). DNA methylation levels
were grouped into low (LM) (< 20%), intermediate (IM)
(20–80%) or high methylation (HM) (> 80%) categories
(Fig. 2) and distributions of these were altered between
NEC and non-NEC ileum samples, reaching statistical
significance for every genomic context tested (Table 3).
CpG methylation was further explored in a spatial
context across each autosome, and we identified global
hypermethylation of NEC ileum, relative to non-NEC
controls, in regions that do not overlap with CGIs. As we
previously observed, CpG methylation within CGIs was
least affected by NEC regardless of CGI location (Fig. 3).
Comparing NEC ileum methylation patterns
with whole‑genome bisulfite sequencing of laser captured
ileal enterocytes

We next compared the results of the current study with
previously published whole-genome bisulfite sequencing (WGBS) data, which were obtained by laser capture microdissection of ileal enterocytes from surgically
resected NEC and non-NEC ileum [13]. A comparison

Table 1 Proportion of CpG sites in different genomic elements that were hyper- or hypomethylated in NEC versus non-NEC control
ileum
Region

Hypermethylated
in non-NEC

All Sites
Prom No CGI
Prom & CGI
Intron/Exon No CGI
Intergenic CGI

Hypermethylated in
NEC

Neither

Fraction
hypermethylated in
non-NEC

Fraction
hypermethylated
in NEC

p value

25,616

71,961

1,990,463

0.013

0.036

NA

3776

15,571

315,307

0.012

0.049

0
0

585

782

240,903

0.002

0.003

10,259

32,288

701,345

0.015

0.046

0

1391

1054

75,600

0.018

0.014

8.81 × 10−274

Intron/Exon & CGI

3198

2496

309,631

0.010

0.008

0

CGI Shores

1153

2874

78,909

0.015

0.036

Intergenic

5637

17,389

418,189

0.013

0.042

6.79 × 10−05

Only CpG sites with differing methylation levels between NEC and non-NEC by > 10% are included

2.21 × 10−93
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Fig. 1 Distribution of methylation of non-NEC (blue) versus NEC (red) ileum by genomic element in A all CpG sites, B promoters without CGI, C
promoter CGIs, D introns/exons without CGI, E intergenic CGI, F CGIs in introns/exons, G CGI shores, H intergenic regions without CGI. Note that
only CpG sites read to a depth of 10 × or more were included in these analyses

Table 2 Differences in distributions of DNA methylation
between neonatal necrotizing enterocolitis and normal control
samples within defined genomic region classes
Region

Diff.med (%)a Diff.med (%)b p value (W.holm)c

A: All Sites

0.60

1.31

0

B: Prom No CGI

0.46

1.58

0

C: Prom & CGI

0.01

0.08

D: Intron/Exon No
CGI

1.40

1.74

0

E: Intergenic CGI

0.14

0.25

0

F: Intron/Exon &
CGI

0.06

0.19

0

G: CGI Shores

0.79

1.27

0

H: Intergenic

1.37

1.66

0

1.19 × 10−253

CGI: CpG island
a

Median difference between NEC ileum and non-NEC ileum

b

Mean difference

c

Adjusted for multiple comparisons using Holm’s method

between the current data and these previously published
WGBS NEC ileum resulted in a correlation coefficient
of 0.972 (p < 2.2 × 10−16) (Fig. 4). For non-NEC controls,
the value was 0.965 (p < 2.2 × 10−16) (Fig. 4A). When we
considered sites between NEC and non-NEC with a test
p value of p < 0.05 in both data sets (laser capture/WGBS
and current data), the correlation coefficients were
0.930 (p < 2.2 × 10−16) between NEC samples and 0.944

(p < 2.2 × 10−16) between non-NEC samples (Fig. 4B).
We next compared the degree of CpG site-specific differential methylation between the two data sets and identified a correlation coefficient of 0.23 (p < 2.2 × 10−16)
when all sites were considered (Fig. 4C) and 0.813
(p < 2.2 × 10−16) when only sites with a test p < 0.05 were
considered (Fig. 4D). These results demonstrate that
there is a considerable degree of correlation between
the targeted genome-wide data presented herein and the
data obtained following laser capture microdissection of
enterocytes and WGBS.
Gene‑specific differential DNA methylation between NEC
and non‑NEC ileum

An analysis of NEC and non-NEC ileum identified
numerous differentially methylated regions (DMRs).
Specifically, we identified 1356 genomic loci contained
within gene bodies (introns/exons) or promoter regions
with a difference in average methylation rate of at least
0.1 between NEC and non-NEC ileum samples (Additional file 2: Table S1A). Of these, 974 were in promoter
regions and could be broken down into those mapping to protein coding genes (n = 333, Additional file 2:
Table S1B), long non-coding RNAs (lincRNAs) (n = 157,
Additional file 2: Table S1C), micro-RNAs (miRNAs)
(n = 75, Additional file 2: Table S1D) and antisense RNAs
(n = 111, Additional file 2: Table S1E). We identified notable genomic loci, including Oncostatin M (OSM). As
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Fig. 2 Comparison methylation category distribution (Hypo ≤ 20%, IM > 20% and < 80%, Hyper ≥ 80%) of non-NEC and NEC ileum by genomic
element

Table 3 Distributions of low methylation (LM, ≤ 20%), intermediate methylation (IM, 20–80%) and high methylation (HM, ≥ 80%) in
genetic elements (NEC vs. non-NEC)
Characteristics

Ileum

All sites

Non-NEC ileum

575,934 (28.93)

705,262 (35.43%)

709,267 (35.63%)

NEC ileum

573,632 (28.82)

640,256 (32.17%)

776,575 (39.01%)

Non-NEC ileum

142,630 (45.24)

120,866 (38.33%)

51,811 (16.43%)

NEC ileum

140,603 (44.59)

112,387 (35.64%)

62,317 (19.76%)

Non-NEC ileum

222,275 (92.27)

9796 (4.07%)

8832 (3.67%)

NEC ileum

222,367 (92.31)

9508 (3.95%)

9028 (3.75%)

Prom No CGI
Prom & CGI
Intron/Exon No CGI
Intergenic CGI
Intron/Exon & CGI
CGI Shores
Intergenic

LM (%)

IM (%)

HM (%)

Non-NEC ileum

66,057 (9.42)

313,258 (44.67)

322,030 (45.92)

NEC ileum

65,109 (9.28)

279,244 (39.82)

356,992 (50.90)

Non-NEC ileum

37,602 (49.74)

14,547 (19.24)

23,451 (31.02)

NEC ileum

37,877 (50.10)

14,125 (18.68)

23,598 (31.21)

Non-NEC ileum

194,501 (62.82)

28,989 (9.36)

86,141 (27.82)

NEC ileum

195,213 (63.05)

28,053 (9.06)

86,365 (27.89)

Non-NEC ileum

23,994 (30.41)

29,250 (37.07)

25,665 (32.52)

NEC ileum

24,064 (30.50)

26,084 (33.06)

28,761 (36.45)

Non-NEC ileum

26,663 (6.38)

194,292 (46.46)

197,234 (47.16)

NEC ileum

26,253 (6.28)

176,432 (42.19)

215,504 (51.53)

Chi-square p
value non-NEC
v. NEC
p < 2.2 × 10−16
p < 2.2 × 10−16
p = 0.03942
p < 2.2 × 10−16
p = 0.02158
p = 0.0002086
p < 2.2 × 10−16
p < 2.2 × 10−16

CGI: CpG island; LM: Low methylation; IM: Intermediate methylation; HM: High Methylation; NEC: Neonatal necrotizing enterocolitis

shown in Fig. 5, the OSM locus displays a reduction in
CpG DNA methylation within its transcriptional regulatory region in NEC samples compared to non-NEC
controls. OSM is a member of the interleukin-6 (IL-6)
cytokine family and has been previously shown to drive

intestinal inflammation in adults with inflammatory
bowel disease [14], and a single nucleotide polymorphism in the OSM locus was associated with increased
risk of IBD [15]. However, the role of OSM during NEC
has not been previously described. OSM can induce
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Fig. 3 Non-NEC (blue) and NEC (red) methylation across Chromosome 1 broken down by genomic element

Fig. 4 A, B Comparison of percent methylation between NEC (red) and non-NEC (blue) between ileum tissue and previously published data [8]
from WGBS of LCM enterocytes. A All sites shared. B Shared sites with p < 0.05 in both methods. C, D Comparison of methylation difference (NEC
minus non-NEC) between ileum tissue and WGBS of LCM enterocytes. C All sites shared. D Shared sites with p < 0.05 in both methods. In each case,
the dashed line represents a correlation value of 1 between the two data sets
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Fig. 5 DNA methylation levels in the Oncostatin M (OSM) locus in ileum samples from NEC (red) and control (black) neonates. Differential
methylation levels are shown across multiple CpG sites that cluster around regulatory elements in and around the flanking regions of the OSM gene
locus

signaling through the JAK-STAT pathway through the
heterodimers gp130 and OSM receptor-β (OSMR) [14].
Additionally, we identified notable differentially methylated gene promoters, including GZMA (15% hypomethylated in NEC) [16], LTB4R (14.6% hypomethylated in
NEC) [17], ISG20 (14.6% hypomethylated in NEC) [18],
PLCB2 (12.7% hypomethylated in NEC) [19], VDR (12%
hypomethylated in NEC) [20], TNIP1 [21] (19% hypermethylated in NEC) and GALNT6 [22] (22% hypermethylated in NEC). These are further discussed below.
We also identified 6793 differentially methylated single CpG sites (DMS) between NEC and non-NEC ileum
samples using a filter of p ≤ 5 × 10−3. Of these, we found
943 in exons, 3405 in introns, 1996 in intergenic regions,
2116 in CGI shores and 22 in enhancers. We identified
484 located within CGIs and, of these, 76 of these were
located within promoters, 143 in exons, 176 in introns
and 156 in intergenic regions (Additional file 2: Table S2).
Ingenuity pathways analysis of differentially methylated
genes

Previous studies have demonstrated that DNA methylation signatures can reveal information about the
molecular phenotypes of tissue or types of cells [23–
25]. Therefore, we explored the functions of genes in
which NEC-specific DMS were identified using Ingenuity Pathways Analysis (IPA) software. Specifically,

we performed an IPA analysis on genes with promoters containing altered CpG methylation (p ≤ 0.05) in
NEC versus non-NEC ileum samples. We identified the
enrichment of genomic regions in numerous notable
biological pathways under the control of a few known
upstream regulators. For example, we found enrichment of genes in pathways including “RhoGDI Signaling”
(p = 5.05 × 10−6), “FXR/RXR activation” (p = 5.35 × 10−6),
“Hepatic Cholestasis” (p = 9.06 × 10−5), “Signaling by Rho
Family GTPases” (p = 4.91 × 10−4) and “PXR/RXR Activation” (p = 5.29 × 10−4) (Additional file 1: Figures S1,
Additional file 2: Table S3A). Predicted upstream regulators of these pathways include HNF1A (p = 6.55 × 10−8),
TFRC (p = 2.79 × 10−5), STAT5A (p = 4.27 × 10−5), CBX5
(p = 8.18 × 10−5) and SMARCA4 (p = 1.29 × 10−4). Predicted downstream targets of these factors are shown in
Additional file 2: Table S3B.
Given that DNA methylation in CGI shores has been
shown to be associated with transcription [13], we next
explored functional associations of genes containing
differentially DMS in CGI shores whose DNA methylation levels were significantly altered between NEC
and non-NEC ileum (p ≤ 0.05). We identified that these
were enriched in several pathways including “molecular
mechanisms of cancer” (p = 9.82 × 10−9), “GNRH signaling” (p = 6.51 × 10−6), “TGF-Signaling” (p = 6.56 × 10−6),
“Thrombin Signaling” (p = 7.04 × 10−6) and “RhoGDI
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Signaling” (p = 1.72 × 10−5) (Additional file 1: Figure S2
and Additional file 2: Table S4A). Predicted upstream
regulators included ERBB2 (p = 7.44 × 10−7), TGFB1
(p = 1.15 × 10−5), KDM1A (p = 2.89 × 10−5), ERG
(p = 5.91 × 10−5) and SOX2 (p = 1.05 × 10−4). Predicted
downstream targets of these factors are shown in Additional file 2: Table S4B.
We further performed IPA analysis of DMS within
CGIs whose DNA methylation levels were significantly
altered between NEC and non-NEC ileum (p ≤ 0.05). We
found that CpG sites within CGIs whose methylation
levels were significantly altered in NEC versus non-NEC
ileum samples were in genes that were enriched in pathways including “Adipogenesis pathway” (p = 9.41 × 10−6),
“CREB Signaling in Neurons” (p = 4.25 × 10−5) and
“1D-myo-inositol Hexakisphosphate Biosynthesis II”
(p = 4.41 × 10−5) (Additional file 1: Figure S3 and Additional file 2: Table S5A). Predicted upstream regulators of
genes in these pathways included SOX2 (p = 1.41 × 10−7),
POU5F1 (p = 9.75 × 10−7) and NANOG (p = 3.36 × 10−5),
(Additional file 2: Table S5B).
Comparison between ileal and colonic NEC‑associated
DNA methylation signatures

We previously performed a comparative analysis of
NEC and non-NEC colon tissue samples using comparable methods described herein for ileum. Comparisons
between the current data and these previous data identified a high degree of correlation between non-NEC and
NEC colon and ileum findings (Fig. 6). Among all sites
targeted, the non-NEC and NEC correlation coefficient
was 0.993 and 0.994, respectively, with a correlation of
0.564 for the difference (not shown). When only sites
between NEC and non-NEC samples were considered

Page 8 of 11

with test p < 0.05, the correlation coefficients were
0.968 (p < 2.2 × 10−16) between NEC samples and 0.962
(p < 2.2 × 10−16) between non-NEC samples (Fig. 6A). A
comparison of the degree of CpG site-specific differential
methylation between the two data sets revealed a correlation coefficient of 0.898 (p < 2.2 × 10−16) when CpG
sites with a test p < 0.05 were considered (Fig. 6B). These
results demonstrate that there is a correlation between
the targeted genome-wide data from the ileum presented
herein and the data obtained from NEC and non-NEC
colon tissue samples [9].
A comparison of ileal and stool NEC‑associated DNA
methylation signatures

We next compared the DNA methylation signatures
identified in NEC versus non-NEC ileum tissue with
those obtained from stool samples from NEC and nonNEC infants. Stool data, which have been published
previously [9], displayed clear hypermethylation in NEC
samples compared to their non-NEC counterparts, and
these trends are highly like those identified in ileal tissue
from NEC and non-NEC infants. As shown in Fig. 7, we
identified a significant correlation between NEC-associated DNA methylation signatures in tissue and stool.

Discussion
The discovery of NEC biomarkers is an important step
toward identifying means of early detection and improving overall management strategies. In this study, we present a comprehensive evaluation of DNA methylation
in NEC ileum tissue samples compared to non-NEC
controls. We observed that ileum samples from infants
with surgical NEC exist in a broadly hypermethylated
state, but these trends are not uniform across all types

Fig. 6 A Comparison of percent methylation between NEC (red) and non-NEC/control (blue) between ileum tissue and previously published colon
tissue 9. Shared sites with p < 0.05 in both tissues. B Comparison of methylation difference (NEC minus non-NEC/control) between ileum tissue and
colon. Shared sites with a p < 0.05 in both tissues. In each case, the dashed line represents a correlation value of 1 between the two data sets
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Fig. 7 A, B Comparison of percent methylation between NEC (red) and non-NEC/control (blue) between ileum tissue and stool. A All sites shared.
B Shared sites with a minimum absolute methylation difference of 5% or more and p < 0.05 in both methods. C, D Comparison of methylation
difference (NEC minus non-NEC/control) between ileum tissue and stool. C All sites shared. D Shared sites with a minimum absolute methylation
difference of 5% or more and p < 0.05 in both methods. In each case, the dashed line represents a correlation value of 1 between the two data sets

of genomic elements. The strongest trend was observed
in genomic regions that do not contain CGIs, whereas
regions containing CGIs showed more balanced DNA
methylation between NEC and non-NEC ileum. The
smallest difference was observed in CGIs located within
promoters. These findings are consistent with our previous observations of DNA methylation in colon and ileum
using whole-genome bisulfite sequencing [8]. However,
because solution phase hybridization was used to target
known genes and regulatory elements, the current study
provides greater insight into the gene-specific changes in
DNA methylation in NEC versus non-NEC tissue.
We also identified several notable genes and related
biological pathways that are associated with NEC-specific differentially methylated loci. We further observed
a significant correlation between NEC-specific DNA
methylation differences identified in the ileum and those
identified in both colon and stool. For example, we identified the promoter region of Granzyme A (GZMA),
which was relatively hypomethylated in NEC versus nonNEC ileum. GZMA is known to be involved in intestinal

epithelial cell detachment participating in the reduction
of adhesion between epithelial cells and basement membranes, through its ability to cleave extracellular matrix
components [16]. Similarly, the Leukotriene B4 receptor
(LTB4R) promoter was also found to be hypomethylated in NEC samples. The protein encoded by this gene
plays an important role in innate immunity, and the
LTB4/LTB4R pathway is involved in the pathogenesis
of the spectrum of human inflammatory diseases [17].
We noted that Interferon Stimulated Exonuclease Gene
(ISG20) gene promoter was also hypomethylated in NEC
samples. ISG20 has anti-viral properties and has been
shown to be positively regulated by IL-22, an important cytokine involved in intestinal defense mechanisms
[26] and recently shown to be a therapeutic strategy to
attenuate inflammation in a pre-clinical model of NEC
[27]. Inositol Polyphosphate-5-Phosphatase D (INPP5D,
SHIP) was also hypomethylated in NEC. INPP5D deficiency is associated with ileitis and it is both involved
in maintaining ileal microbial homeostasis and reduced
levels have been reported in individuals with Crohn’s
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disease [18]. Phospholipase C Beta 2 (PLCB2), which is
involved in epithelial repair and integrity in the intestine
[19], was also hypomethylated in its promoter region in
NEC, as well as the vitamin D receptor (VDR), which
protects against intestinal injury of NEC partly through
suppressing the expression of the innate immune receptor, toll-like receptor 4 (TLR4) [20]. TNFAIP3 Interacting
Protein 1 (TNIP1), the promoter of which was hypermethylated in NEC, helps to prevent intestinal inflammation by restricting intestinal epithelial cell death and
preserving tissue integrity [21].
Notably, the trends identified in DNA methylation patterns of surgical NEC ileum samples were also detected
in stool samples of affected infants. As observed in the
ileal tissue, stool samples of NEC infants showed a broad
degree of hypermethylation compared to their non-NEC
counterparts. Furthermore, as in NEC ileal tissue, CpG
sites in stool DNA were the least likely to be hypermethylated in NEC when they were in CpG islands in promoters. Also, as in NEC ileal tissue, the CpG sites in stool
DNA that exhibited the greatest degree of hypermethylation in NEC were found to be in introns/exon sequences
that do not contain CpG islands and intergenic regions.
The limitations of this case–control study include the
inaccessible gender information for all surgically resected
infants due to the nature of the IRB protocol and the relatively small sample size. Therefore, a further investigation of a larger cohort of both tissue and stool samples
coupled with available clinical information is warranted.
Furthermore, this was a cross-sectional study performed
using NEC tissue and stool samples from infants with
active NEC. Because there are no methods to predict the
onset of NEC in premature infants, the rapid onset of
NEC can result in tissue injury and necrosis. If the epigenomic changes that we identified in the ileal tissue and
stool of infants with NEC are evident in early stages of
NEC, this may provide an opportunity to develop noninvasive stool-based screening tools for its early detection. In particular, the early detection of NEC is key to
the development of new therapeutics that can be implemented before the disease is clinically apparent. Future
efforts will involve prospective studies of stool samples
collected longitudinally so that we may explore whether
DNA methylation changes appear prior to the onset
of NEC. Future efforts will also explore whether hypermethylation, as we have observed in NEC, is a feature of
other necrotized tissues.

Conclusion
In conclusion, when comparing NEC tissues with nonNEC tissues, we observed broadly hypermethylated ileal
NEC samples. We also found that broad DNA hypermethylation can be detected in stool samples from
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affected individuals. These findings, in addition to similar observations in the colon, suggest that epigenomic
dysregulation is a significant feature of surgical NEC and
may provide additional insights into NEC pathogenesis.
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